Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns

  • Share on Google+

GBI Research

2011 May 09

164 Pages (PDF)




Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns

Summary

GBI Research has released its latest research Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns, which essentially provides insights on lifestyle disorders therapeutics sales and price forecasts until 2016. The report also examines the global lifestyle disorders therapies treatment usage patterns. In addition, the geographical distribution of lifestyle disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the lifestyle disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2016. The report provides an in-depth analysis of the top five lifestyle disorders therapeutic indications, which are erectile dysfunction, obesity, alopecia, smoking cessation and alcohol dependence. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving lifestyle disorders therapies is also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Researchs analysis showed that the global lifestyle disorders therapeutics market was segmented into five indications namely erectile dysfunction with the market size of $3.2 billion in 2009, followed by obesity, alopecia, smoking cessation and finally the alcohol dependence market.

Scope

The scope of this report includes - 
- Annualized market data for the lifestyle disorders therapeutics market from 2001 to 2009, with forecasts to 2016.
- Market analysis for the five major indications in the global lifestyle disorders therapeutics market which includes Erectile dysfunction, Obesity, Alopecia, Smoking Cessation and Alcohol dependence.
- Data and analysis on the lifestyle disorders therapeutics market in the leading geographies of the world  the US, the UK, Germany, France, Italy, Spain, and Japan. 
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- The competitive landscape of the global lifestyle disorders therapeutics market 
- Key M&A activities and licensing agreements that took place from 2004 to 2010 in the lifestyle disorders therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 
- Build effective strategies to launch their pipeline products by identifying potential geographies. 
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps. 
- Develop key strategic initiatives by studying the key strategies of top competitors. 
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. 
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 10
2 Lifestyle Disorders  Market  Introduction 12
2.1 GBI Research Report Guidance 13
3 Global Erectile Dysfunction Therapeutics Market 14
3.1 Market Overview 14
3.1.1 Market Forecasts 14
3.1.2 Annual Cost of Therapy 16
3.2 Treatment Usage Patterns 17
3.2.1 Diseased Population 19
3.2.2 Treatment Seeking Population 21
3.2.3 Diagnosis Population 23
3.2.4 Prescription Population 25
3.3 Geographical Segmentation 27
3.3.1 Market Share Analysis 27
3.4 Product Analysis 28
3.4.1 Viagra (sildenafil citrate) 28
3.4.2 Cialis (tadalafil) 28
3.4.3 Levitra (verdenafil HCL) 29
3.4.4 Caverject (Alprostadil) 29
3.4.5 Muse (alprostadil) 29
4 Global Obesity Therapeutics Market 30
4.1 Market Overview 30
4.1.1 Market Forecasts 30
4.1.2 Annual Cost of Therapy 32
4.2 Treatment Usage Patterns 33
4.2.1 Diseased Population 35
4.2.2 Treatment Seeking Population 36
4.2.3 Diagnosis Population 37
4.2.4 Prescription Population 38
4.3 Geographical Segmentation 39
4.3.1 Market Share Analysis 39
4.3.2 Market Forecast- US, EU-5, Japan 40
4.4 Product Analysis 42
4.4.1 Xenical (Orlistat 120mg) and Alli (Orlistat 60mg) 42
4.4.2 Bontril PDM (Phendimetrazine Tartarate) 43
4.4.3 Benzphetamine hydrochloride 43
5 Global Alopecia Therapeutics Market 44
5.1 Market Overview 44
5.1.1 Market Forecasts 45
5.1.2 Annual Cost of Therapy 46
5.2 Geographical Segmentation 47
5.2.1 Market Share Analysis 47
5.2.2 Market Forecast- US, EU-5, Japan 48
5.3 Product Analysis 49
5.3.1 Propecia (Finasteride) 49
5.3.2 Rogaine (Minoxidil) 49
5.4 Global Areata Alopecia Market 50
5.4.1 Market Overview 50
5.4.2 Market Forecasts 52
5.4.3 Annual Cost of Therapy 53
5.4.4 Treatment Usage Patterns 54
5.4.5 Geographical Segmentation 60
5.5 Global Androgenetic Alopecia Market 62
5.5.1 Market Overview 62
5.5.2 Market Forecasts 64
5.5.3 Annual Cost of Therapy 65
5.6 Treatment Usage Patterns 66
5.6.1 Diseased Population 68
5.6.2 Treatment Seeking Population 69
5.6.3 Diagnosis Population 70
5.6.4 Prescription Population 71
5.6.5 Geographical Segmentation 72
6 Global Smoking Cessation Market 74
6.1 Market Overview 74
6.1.1 Market Forecasts 74
6.1.2 Annual Cost of Therapy 76
6.2 Treatment Usage Patterns 77
6.2.1 Diseased Population 79
6.2.2 Treatment Seeking Population 80
6.2.3 Diagnosis Population 81
6.2.4 Prescription Population 82
6.3 Geographical Segmentation 83
6.3.1 Market Share Analysis 83
6.3.2 Market Forecast  US, EU-5, Japan 84
6.4 Product Analysis 85
6.4.1 Zyban(buproprion hydrochloride) 85
6.4.2 Nicotrol 85
6.4.3 Nicoderm 85
6.4.4 Nicorette 86
6.4.5 Chantix (varenicline tartarate) 86
7 Global Alcohol Dependence Market 87
7.1 Market Overview 87
7.1.1 Market Forecasts 88
7.1.2 Annual Cost of Therapy 90
7.2 Treatment Usage Patterns 91
7.2.1 Diseased Population 93
7.2.2 Treatment Seeking Population 94
7.2.3 Diagnosis Population 95
7.2.4 Prescription Population 96
7.3 Geographical Segmentation 97
7.3.1 Market Share Analysis 97
7.3.2 Market Forecast  US, EU-5, Japan 98
7.4 Product Analysis 99
7.4.1 Campral (acamprosate calcium) 99
7.4.2 Antabuse (disulfurum) 99
8 Global Lifestyle Disorders Therapeutics Market  Pipeline Analysis 100
8.1 Global Erectile Dysfunction Therapeutics Market 100
8.1.1 Major Pipeline Products by Phase 100
8.1.2 Major Late Stage Pipeline Molecules 101
8.2 Global Obesity Therapeutics Market 105
8.2.1 Pre-clinical and Discovery Phase 105
8.2.2 Phase I 108
8.2.3 Phase II 109
8.2.4 Phase III 111
8.2.5 Major Late Stage Pipeline Molecules 112
8.2.6 Victoza (liraglutide) 112
8.3 Global Alopecia Therapeutics Market 113
8.3.1 Major Late Stage Pipeline Molecules 113
8.4 Global Smoking Cessation Therapeutics Market 114
8.4.1 Pre-clinical and Discovery Phase 114
8.4.2 Phase I 114
8.4.3 Phase II 115
8.4.4 Phase III 116
8.4.5 Major Late Stage Pipeline Molecules 117
8.5 Global Alcohol Dependence Therapeutics Market 118
8.5.1 Phase I 118
8.5.2 Phase II 119
8.5.3 Phase III 121
8.5.4 Major Late Stage Pipeline Molecules 122
8.5.5 Nalfemene 122
8.5.6 NS11 123
9 Global Lifestyle Disorders Therapeutics Market  Competitive Landscape 124
9.1 Eli Lilly 124
9.1.1 Overview 124
9.1.2 Business Description 124
9.1.3 Major Products in the Lifestyle Disorder Therapeutics Market 125
9.2 Bayer 125
9.2.1 Overview 125
9.2.2 Business Description 126
9.2.3 Major Products in the Lifestyle Disorder Therapeutics Market 127
9.3 VIVUS Inc 127
9.3.1 Overview 127
9.3.2 Business Description 128
9.4 F. Hoffmann-La Roche Ltd. 128
9.4.1 Overview 128
9.4.2 Business Description 129
9.4.3 Major Products in the Lifestyle Disorder Therapeutics Market 129
9.5 Abbott Laboratories 130
9.5.1 Overview 130
9.5.2 Business Description 130
9.5.3 Major Products in the Lifestyle Disorder Therapeutics Market 131
9.6 GlaxoSmithKline 132
9.6.1 Overview 132
9.6.2 Business Description 132
9.6.3 Major Products in the Lifestyle Disorder Therapeutics Market 133
9.7 Shire Plc 133
9.7.1 Overview 133
9.7.2 Business Description 134
9.7.3 Major Products in the Lifestyle Disorder Therapeutics Market 134
9.8 Pfizer 135
9.8.1 Overview 135
9.8.2 Business Description 136
9.8.3 Major Products in the Lifestyle Disorder Therapeutics Market 136
9.9 Novartis 138
9.9.1 Overview 138
9.9.2 Business Description 139
9.9.3 Major Products in the Lifestyle Disorder Therapeutics Market 139
9.10 Teva Pharmaceuticals 140
9.10.1 Overview 140
9.10.2 Business Description 141
9.10.3 Major Products in the Lifestyle Disorder Therapeutics Market 141
9.11 Watson Pharmaceuticals 142
9.11.1 Overview 142
9.11.2 Business Description 143
9.11.3 Major Products in the Lifestyle Disorders Therapeutics Market 143
9.12 Merck & Co 144
9.12.1 Overview 144
9.12.2 Business Description 145
9.12.3 Major Product in the Lifestyle Disorders Therapeutics Market 146
9.13 Johnson & Johnson 146
9.13.1 Overview 146
9.13.2 Business Description 147
9.13.3 Major Products in the Lifestyle Disorders Therapeutics Market 147
9.14 Orexigen Therapeutics, Inc 147
9.14.1 Overview 147
9.14.2 Financial Overview 148
9.14.3 Major Products in the Lifestyle Disorders Therapeutic Market 148
9.15 Takeda Pharmaceutical Company Limited 148
9.15.1 Overview 148
9.15.2 Business Overview 148
9.15.3 Major Products in the Lifestyle Disorders Therapeutic Market 149
9.16 7TM Pharma 149
9.16.1 Overview 149
9.16.2 Major Products in the Lifestyle Disorders Therapeutic Market 149
10 Global Lifestyle Disorders Therapeutics Market  Strategic Consolidations 150
10.1 Mergers and Acquisitions 150
10.1.1 Deals by Geography 150
10.1.2 Deals by Indications 151
10.1.3 Deals by Year 152
10.1.4 Major Licensing Agreements, 2004-2010 152
10.2 Licensing Agreements 155
10.2.1 Licensing Agreements by Geography 155
10.2.2 Licensing Agreements by Indications 156
10.2.3 Licensing Agreements by Year 157
10.2.4 Major Licensing Agreements, 2004-2010 158
11 Global Lifestyle Disorders Market  Appendix 160
11.1 Market Definitions 160
11.2 Abbreviations 160
11.3 Research Methodology 161
11.3.1 Secondary Research 161
11.3.2 Primary Research 161
11.3.3 Forecasts 162
11.3.4 Expert Panel Validation 163
11.4 Contact Us 163
11.5 Disclaimer 163
11.6 Sources 164
Eli Lilly 
Bayer 
VIVUS Inc 
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
GlaxoSmithKline 
Shire Plc 
Pfizer 
Novartis 
Teva Pharmaceuticals
Watson Pharmaceuticals
Merck & Co 
Johnson & Johnson
Orexigen Therapeutics, Inc
Takeda Pharmaceutical Company Limited
7TM Pharma				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement